Skip to main content
. 2016 May 17;15:78. doi: 10.1186/s12933-016-0393-6

Fig. 2.

Fig. 2

a Hazard ratios (HR) and 95 % CI for risk of MACE+ for treatment with BIL versus comparator insulin in the individual studies. BB basal-bolus insulin therapy, BIL basal insulin peglispro, BO basal only insulin therapy, N insulin naïve prior to study, P taking insulin prior to study, T1 type 1 diabetes, T2 type 2 diabetes